1 / 11

Cervix Committee

Cervix Committee. GCIG Trials. Thirty Four Delegates attended the committee meeeting and one invited guest Active, Developing and proposed trials were discussed. Currently Active GCIG Trials.

wilton
Download Presentation

Cervix Committee

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cervix Committee

  2. GCIG Trials • Thirty Four Delegates attended the committee meeeting and one invited guest • Active, Developing and proposed trials were discussed.

  3. Currently Active GCIG Trials • GOG 0219: A phase III, randomized trial of weekly CDDP and RT versus CDDP, Tirapazamine and RT in stage IB2-IVA cervical carcinoma limited to the pelvis. • Continues to accrue • NCIC – CTG participating • Some difficulty with Tirapazamine distribution.

  4. JGOG Phase III study of S-1 + Cisplatin in cervical cancer • 52 of 360 pts accrued • Participation with Korea and Taiwan • No further group participation planned by the sponsoring company

  5. Currently Active Trial without Intergroup Participation • EORTC 55994: Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO stage Ib2, IIa>4 cm or IIb cervical cancer. • 100 pts left to accrue at 5/month • No intergroup particiaption

  6. GOG 240: Cis/Taxol +/- Bev vs Topo/Taxol +/- Bev in stage IVB cervix cancer • Just activated • Intergroup participation is expected

  7. Developing Trials • RTOG 0724: ChemoRT with and without adjuvant chemotherapy in high risk cervix cancer after hysterectomy • Near activation • Will need intergroup participation

  8. KGOG 0801: RT vs CRT in intermediate risk cervix cancer after hysterectomy • Near activation • Will be done in collaboration with GOG

  9. GOG A Phase III Trial of 12 months of Oral Pazopanib versus Placebo Among Women With FIGO Stage IB2, > 4 cm IIA and IIB-IVA Cervical Cancer Limited to the Pelvis After Responding to Front-Line Weekly Cisplatin Chemotherapy and Pelvic Radiation • Early in the development • Discussion around a possible 2 X 2 design

  10. GOG CVM0503: CRT vs CRT + Cetuximab in patients with para-aortic metastasis • Building on head and neck trial • Preceded by a Phase 1 trial

  11. New Concepts/projects • ANZGOG adjuvant chemotherapy after chemo/RT • EMBRACE trial • Vulvar Cancer Randomized Trial

More Related